Evidence map›Paper›PMID 40248135›Full record

ArticleBiochemistry and biophysics reports2025

Development and validation of a recombinant human TNF-α based ELISA to detect and quantify adalimumab.

Dinesh Kumar Saini, Manjunath S Devaramani, Hemalakshmi Shanmugavel, Syeda Zuhin Tabassum, Kiran Kumar Mudnakudu-Nagaraju, Jalahalli Mariswamy Siddesha, Radhakrishna Shetty

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dinesh Kumar SainiDivision of Biochemistry, School of Life Sciences, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India.
Manjunath S DevaramaniDenovo Biolabs Pvt Ltd., Electronic City, Phase I, Bengaluru, 560100, India.
Hemalakshmi ShanmugavelDenovo Biolabs Pvt Ltd., Electronic City, Phase I, Bengaluru, 560100, India.
Syeda Zuhin TabassumDenovo Biolabs Pvt Ltd., Electronic City, Phase I, Bengaluru, 560100, India.
Kiran Kumar Mudnakudu-NagarajuDepartment of Biotechnology & Bioinformatics, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India.
Jalahalli Mariswamy SiddeshaDivision of Biochemistry, School of Life Sciences, JSS Academy of Higher Education & Research, SS Nagar, Mysuru, 570015, India.
Radhakrishna ShettyNational Food Institute Research Group for Chemical Risk Assessment and GMO Research Group for Microbial Biotechnology and Biorefining, Henrik Dams Allé, 2800, Kgs. Lyngby, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adalimumab, a humanized IgG1 monoclonal antibody is currently used to treat inflammatory diseases. However, a sensitive, in-house ELISA for evaluating inter- and intra-individual pharmacokinetic variability of adalimumab remains limited. In this study, an ELISA was developed to measure adalimumab levels, using recombinant human TNF-α (rhTNF-α) as capture antibody. Initially, surface plasma resonance showed acceptable binding kinetics (K

Indexed as

AdalimumabArthritisBioanalysisELISAInflammationPharmacokineticsTNF-Alpha

Identifiers

PMID40248135
PMCPMC12005340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.